Goldman Sachs Sticks to Its Buy Rating for BioNTech SE (BNTX)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
BioNTech (NasdaqGS:BNTX) Faces Sales Decline To €2,751 Million In 2024 And Projects Lower 2025 Revenue
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
The Pharma Letter1d
BioNTech revenues beat forecasts despite declining
Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...
UBS Sticks to Their Hold Rating for BioNTech SE (BNTX)
In a report released today, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of ...
SVB Wealth LLC Buys Shares of 1,788 BioNTech SE (NASDAQ:BNTX)
SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...
BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...